301 related articles for article (PubMed ID: 20361469)
1. HDAC inhibitors in cancer care.
Tofilon PJ; Camphausen K
Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
[TBL] [Abstract][Full Text] [Related]
2. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic.
Shabason JE; Tofilon PJ; Camphausen K
J Cell Mol Med; 2011 Dec; 15(12):2735-44. PubMed ID: 21362133
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Khan O; La Thangue NB
Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
5. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
8. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
Schobert R; Biersack B
Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
[TBL] [Abstract][Full Text] [Related]
9. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X; Ezzeldin HH; Diasio RB
Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
12. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
13. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.
McClure JJ; Li X; Chou CJ
Adv Cancer Res; 2018; 138():183-211. PubMed ID: 29551127
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
15. The biology of HDAC in cancer: the nuclear and epigenetic components.
Hagelkruys A; Sawicka A; Rennmayr M; Seiser C
Handb Exp Pharmacol; 2011; 206():13-37. PubMed ID: 21879444
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
17. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
18. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Richardson PG; Mitsiades CS; Laubach JP; Hajek R; Spicka I; Dimopoulos MA; Moreau P; Siegel DS; Jagannath S; Anderson KC
Leuk Res; 2013 Jul; 37(7):829-37. PubMed ID: 23582718
[TBL] [Abstract][Full Text] [Related]
19. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
20. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]